$37.00
-0.82-2.17%
Last update: Oct 16, 4:02 PM
$36.95
-0.87-2.3%
Genmab AS
GMABNASDAQ
Genmab (GMAB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Genmab (GMAB) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided revenue in the range of $4.33B - $4.53B for the period.
Compared to prior guidance, Genmab raised its revenue forecast from a prior range of $4.07B - $4.39B.
Genmab has issued 17 guidance updates between November 3, 2022 and August 6, 2026. During this period, the company raised its outlook 10 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.31 | $0.17 | $0.44 | $0.46 |
| Actual | $4.91 | $0.08 | $0.05 | $0.65 |
| Surprise | +1483.9% | -51.2% | -88.6% | +40.4% |
| Revenue | ||||
| Estimate | $5.81B | $4.71B | $4.40B | $4.21B |
| Actual | $1.16B | $896.0M | $1.06B | $1.02B |
| Surprise | -80.1% | -81.0% | -76.0% | -75.7% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.33 | $0.26 | $0.14 | $0.47 |
| Revenue | ||||
| Consensus | $6.64B | $6.97B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $4.91 | $0.31 | 1483.9 % |
| Q1 | May 7, 2026 | $0.08 | $0.17 | -51.2 % |
| Q4 | Feb 17, 2026 | $0.05 | $0.44 | -88.6 % |
| Q3 | Nov 6, 2025 | $0.65 | $0.46 | 40.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $1.16B | $5.81B | -80.1 % |
| Q1 | May 7, 2026 | $896.00M | $4.71B | -81.0 % |
| Q4 | Feb 17, 2026 | $1.06B | $4.40B | -76.0 % |
| Q3 | Nov 6, 2025 | $1.02B | $4.21B | -75.7 % |
